Dato-DXd for triple-negative breast cancer brain metastases
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies Dato-DXd (an antibody-drug medicine) in people with triple-negative breast cancer that has spread to the brain. It aims to see how well it controls brain tumors when they are newly found or growing after other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed breast cancer that is triple-negative (no hormone receptors) based on lab testing
- You have brain metastases that are new (untreated) or growing after prior local treatment
- Your brain metastases can be measured on scans, and there’s no need for immediate brain radiation or surgery
- Your general strength is good enough (KPS at least 70, ECOG 0–2) and you expect to live at least 3 months
- You can safely take the study treatment and meet blood, kidney, and liver test requirements
- You’ve had enough time pass since prior treatments (washout) and you can give informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called datopotamab deruxtecan for people with HER2-negative breast cancer that has spread to the brain. It looks at how well the drug works against brain metastases.
This study is looking at a new antibody-drug treatment (Dato-DXd) for people with triple-negative breast cancer that has spread and hasn't been treated yet. It's designed to attack cancer cells directly and may be an option for those who can't have immunotherapy.
This trial tests a new drug called Dato-DXd for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to help stop the cancer from growing.
This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.
This trial tests a drug called Trastuzumab Deruxtecan (T-DXd) for people with brain tumors that are either glioblastoma or have spread from other cancers. Doctors will see if T-DXd can shrink tumors or slow their growth, and they will collect tumor tissue during surgery or biopsy to study how the drug works.
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
Hear when a new Breast Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.